Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Chana Fuchs"'
Autor:
Jee Chung, Steven Lemery, Edwin C. Y. Chow, Sandra J. Casak, Amy E. McKee, Richard Pazdur, Sarah J Schrieber, Weishi Yuan, Thomas Gwise, Lisa Rodriguez, Anne M. Rowzee, Sue Lim, Chana Fuchs, Patricia Keegan
Publikováno v:
Clinical Cancer Research. 24:4365-4370
Passage of the Biologics Price Competition and Innovation Act of 2009 created an abbreviated licensure pathway for biosimilar products. The FDA approved ABP215 (MVASI, bevacizumab-awwb; Amgen) as a biosimilar to U.S.-licensed Avastin (bevacizumab; Ge
Autor:
Patricia Keegan, Wen Jin Wu, Andrea Weir, Michelle R. Frazier-Jessen, Wendy C. Weinberg, Melanie Hartsough, Chana Fuchs
Publikováno v:
Cancer and Metastasis Reviews. 24:569-584
An increasing number of monoclonal antibodies for cancer diagnosis and treatment are in clinical use and in the development pipeline, with more expected as new molecular targets are identified. As with all drugs, product quality, an appropriate pre-c
Autor:
Eric Glasgow, Robert K. Druger, Edward M. Levine, Suzanne Giordano, Nisson Schechter, Chana Fuchs
Publikováno v:
Scopus-Elsevier
In efforts to determine the primary structure of intermediate filament proteins in the goldfish visual pathway, we isolated clones from a retinal lambda gt11 cDNA expression library that represent goldfish vimentin. We show that there are at least tw
Publikováno v:
PDA journal of pharmaceutical science and technology. 68(1)
Available guidance documents, such as the International Conference on Harmonization (ICH) Q5a: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, delineate principles to consider when assessing the vi
Autor:
Giuditta Mantile, Anil B. Mukherjee, Eleonora Cordella-Miele, Lucio Miele, Alessandro Peri, Chana Fuchs
Publikováno v:
Biotechnology Progress. 16:17-25
Numerous biopharmaceuticals and other recombinant biotechnology products are made in prokaryotic hosts. However, bacterial production of native, biologically active eukaryotic proteins is rarely possible for disulfide-bonded and/or multisubunit prote
Publikováno v:
Journal of Cellular Biochemistry. 73:164-175
Strikingly increased expression of notch-1 has been demonstrated in several human malignancies and pre-neoplastic lesions. However, the functional consequences of notch-1 overexpression in transformed cells remain unclear. We investigated whether end
Autor:
Sharon Sickafuse, Hong Zhao, Stacy S. Shord, Richard Pazdur, Kun He, Huanyu Chen, Martin H. Cohen, Chana Fuchs, Patricia Keegan
Learning Objectives Compare survival outcomes among patients with SCCHN treated with a platinum/5 -FU regimen with and without cetuximab. Compare adverse event profiles among patients with SCCHN treated with a platinum/5 -FU regimen with and without
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8a8a8801fb6ecaa6c173d0f26277e7
https://europepmc.org/articles/PMC3639534/
https://europepmc.org/articles/PMC3639534/
Publikováno v:
The Journal of Comparative Neurology. 350:452-462
The adult goldfish retina and optic nerve display continuous growth, plasticity, and the capacity to regenerate throughout the animal's life. The intermediate filament proteins in this pathway are different from those in adult mammalian nerves, which
Publikováno v:
Scopus-Elsevier
The goldfish visual pathway displays a remarkable capacity for continued development and plasticity. The intermediate filament proteins of this pathway do not match the intermediate filament protein composition of adult higher vertebrate neurons, whi
Autor:
Kallappa Koti, Anne M. Pilaro, Kaushikkumar A. Shastri, Patricia Keegan, Richard Pazdur, Monica Hughes, Hong Zhao, Karen D. Weiss, Mark D. Rothmann, Ruth Cordoba-Rodriguez, Ruthann M. Giusti, Angela Yuxin Men, Chana Fuchs
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(5)
Purpose: To describe the Food and Drug Administration review and marketing approval considerations for panitumumab (Vectibix) for the third-line treatment of patients with epidermal growth factor receptor–expressing metastatic colorectal carcinoma.